Nelfinavir ( DrugBank: Nelfinavir )


3 diseases
告示番号疾患名(ページ内リンク)臨床試験数
49全身性エリテマトーデス1
265脂肪萎縮症4
331特発性多中心性キャッスルマン病1

49. 全身性エリテマトーデス


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02066311
(ClinicalTrials.gov)
September 201412/2/2014Nelfinavir in Systemic Lupus ErythematosusNelfinavir in Systemic Lupus Erythematosus: A Pilot Phase IIa Clinical TrialSystemic Lupus ErythematosusDrug: NelfinavirNorthwell HealthNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Terminated18 Years65 YearsAll15Phase 2United States

265. 脂肪萎縮症


臨床試験数 : 112 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00192660
(ClinicalTrials.gov)
February 200312/9/2005HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First TimeHIV-Associated Lipodystrophy Syndrome;Cardiovascular DiseaseDrug: Lamivudine;Drug: Stavudine;Drug: Didanosine;Drug: Zidovudine;Drug: Tenofovir;Drug: Abacavir;Drug: Efavirenz (EFV);Drug: Nevirapine;Drug: Indinavir;Drug: Saquinavir;Drug: Amprenavir;Drug: Ritonavir;Drug: Nelfinavir;Drug: Tipranavir;Drug: enfuvirtide (T20)Kirby InstituteSt Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI)Completed18 YearsN/ABoth80Phase 4Australia
2NCT00457665
(ClinicalTrials.gov)
February 20024/4/2007Mechanisms of Lipodystrophy in HIV-Infected PateintsMecahnisms of Lipodystrophy in HIV-Infected PatientsHIV InfectionsDrug: Nelfinavir;Drug: EfavirenzUniversity of Texas Southwestern Medical CenterBristol-Myers Squibb;GlaxoSmithKlineCompleted18 Years70 YearsAll56Phase 4United States
3NCT00017758
(ClinicalTrials.gov)
June 200111/6/2001The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering DrugsThe Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase InhibitorsHIV Infections;HIV Seronegativity;LipodystrophyDrug: Pravastatin sodium;Drug: Simvastatin;Drug: Atorvastatin calcium;Drug: Nelfinavir mesylate;Drug: EfavirenzNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted18 Years60 YearsBoth56Phase 1United States
4NCT00006190
(ClinicalTrials.gov)
November 200025/8/2000A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop LipodystrophyThe Study of Mechanisms of Lipodystrophy in HIV-Infected PatientsHIV Infections;LipodystrophyDrug: Nelfinavir mesylate;Drug: Stavudine;Drug: Lamivudine;Drug: EfavirenzNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompleted18 Years70 YearsBothPhase 4United States

331. 特発性多中心性キャッスルマン病


臨床試験数 : 33 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02080416
(ClinicalTrials.gov)
July 20144/3/2014Nelfinavir for the Treatment of Gammaherpesvirus-Related TumorsA Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related TumorsNon-Hodgkin Lymphoma;Hodgkin Lymphoma;Kaposi Sarcoma;Gastric Cancer;Nasopharyngeal Cancer;EBV;Castleman DiseaseDrug: NelfinavirSidney Kimmel Comprehensive Cancer CenterNULLTerminated18 YearsN/ABoth1Phase 0United States